窑Original Article窑 Bladder cancer is one of the most common cancers in the world. Among the cases, most (75% ) are superficial bladder cancer (SBC). Patients with SBC are at high risk of relapse after surgery with concomitant radiotherapy and chemotherapy. Thus it is necessary to find an efficient immunotherapy for preventing relapse of bladder cancer.
Human interleukin2 (hIL2) is a T cell growth factor and signaling modulator. It plays an important role in immunoregulation [1] . Streptavidin (SA) has an extraordinarily strong affinity for biotin. This strong noncovalent interaction is widely made use of in many areas of biomedicine [2] . Based on this strong interaction and the ability of biotin to be incorporated easily onto the tumor cell surface, we have developed a bifunctional fusion protein, streptavidintagged hIL2 (SAhIL2), which may efficiently bind to the biotinylated tumor cells via its SA moiety, anchor the hIL2 moiety at the local site of SBC, trigger a more effective antitumor immune response, and thus be applied in the clinical treatment of patients with SBC. In this study, based on a mouse orthotopic model of SBC that we successfully established [3] , we assessed the antitumor effects of SAhIL2 by its immobilization on the mucosal surface of the mouse bladder to provide some experimental basis for the application of SAhIL2 in bladder cancer therapy.
The mouse bladder cancer cell line (MB49) was kept by our research institution. RPMI1640 and 0.25% trypsin were provided by Gemon BioMedical Technology Co., Ltd. Fetal bovine serum was provided by Hangzhou Sijiqing Biological Engineering Material Co., Ltd. The 100 female C57BL/6 mice (aged 68 weeks, weighing 1620 g, Quality Certification Number: SCXK Guangdong, 20070015) were provided by Experimental Animal Center, Southern Medical University. IntimaII closedtype venous catheters (0.7 mm 伊 19 mm, 24G) were provided by Becton Dickinson Medical Devices Co., Ltd., Suzhou. Antimouse IL2Rα antibody was provided by the R&D Corporation. The lactate dehydrogenase (LDH) kits were provided by the Promega Corporation. SAhIL2 fusion protein was prepared by our lab [4] .
Following sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE), SAhIL2 was transferred onto a nitrocellulose membrane by semidry electroblotting. The membrane was incubated with 5% nonfat milk powder at 37益 for 2 h, and then incubated with 1:3000 diluted mouse antihIL2 monoclonal antibody for 1 h. The membrane was washed 6 times with phosphate buffered saline Tween20 (PBST) and then incubated by 1:500 diluted horseradish peroxidase (HRP)conjugated goat antimouse IgG as a second antibody at room temperature for 1 h. The HRP activity was demonstrated by diaminobenzidin (DAB) kit (Wuhan Boster biological Technology, Ltd.).
Wellgrowing MB49 cells were used and adjusted to a density of 5 × 10 6 /mL. SulfoNHSLCLCBiotin was added to reach an ultimate concentration of 1 mg/mL. The cells were incubated at 37益 for 60 min. Then SAhIL2 was added and the cells were incubated for another 60 min. The cells were washed and then incubated with IL2 monoclonal antibody at 37益 for 30 min. The cells were washed again and then incubated with 10 滋 L of fluorochrome conjugated second antibody at room temperature away from the light for 30 min. After centrifugation and washing, 500 滋 L of washing fluid was added per tube to resuspend the cells. The suspension was transferred to an assay tube for flow cytometric analysis. The extent of modification of tumor cells by SAhIL2 was assessed.
Human peripheral blood lymphocytes (hPBL) were separated and 5 mL of RPMI1640 complete medium and 10 滋 L of polyhydroxyalkanoates (PHA) (ultimate concentration = 10 滋 g/mL) were added and tapped to mix. The cell suspension was then transferred to a flask and incubated with 5% CO 2 at 37益 for 48 h. Doubling dilution of renatured SAhIL2 (initial concentration = 10 滋 g/mL) and standard IL2 was performed in a 96well plate, with 100 滋 L per well and 3 wells for each dilution. Medium control (RPMI1640 100 滋 L) was set. A volume of 100 滋 L of PHAactivated hPBL (2 伊 10 5 /mL) were added to each well and incubated with 5% CO 2 at 37益 for 24 h. A volume of 10 滋 L of CCK8 per well was then added and incubated with 5% CO 2 at 37益 for 4 h. Absorbance ( value) was detected under the wavelength of 450 nm by a plate reader. The activity of SAhIL2 (U/mL) = dilution of SAhIL2 having 50% of the maximum of standard IL2/dilution of standard IL2 having 50% of the maximum of standard IL2 伊 activity of standard IL2 (U/mL).
MB49 cells were detached with trypsin and washed 3 times with phosphate buffered saline (PBS) (pH 7.4). Cell density was then adjusted to 5 伊 10 6 /mL. SulfoNHSLC LCBiotin was added to reach an ultimate concentration of 1 mg/mL. The cells were incubated at 37益 for 30 min and then washed 3 times with PBS. Then the cells were incubated with SAhIL2 (100 ng/mL) at room temperature for 60 min. SAGFP (100 ng/mL) was used as a negative control. After PBS washing (800 r/min 伊 5 min centrifugation), RPMI1640 was added. Freezing and thawing of the cells in liquid nitrogen was repeated 3 times. The suspension of broken cells, now being the sample, was tested for activity of SAhIL2 according to the method in subsection mentioned above.
When in the log phase, the cultured MB49 cells were detached with 0.25% trypsin and washed with PBS 3 times. Cell density was adjusted to 1 伊 10 7 /mL with RPMI1640 containing 1% fetal bovine serum. After the female C57BL/6 mice were anesthetized by intraperitoneal 0.6% pentobarbital sodium at 60 mg/kg, sterile procedures of urethral catheterization were performed with a venous catheter. Bladder perfusion started with 0.1 mL of PBS to wash away urine. A volume of 0.1 mL hydrochloric acid (HCl) (0.1 mol/L) was then given and after 15 s drained. A volume of 0.1 mL sodium hydroxide (NaOH) (0.1 mol/L) was then given and after 5 s drained. After 3 times of PBS washing, 0.1 mL of MB49 (about 1 伊 10 6 cells) was given in a 2h perfusion for implantation of the tumor cells [3] .
On days 1, 3, 5, and 7 after the bladder mucosa was biotinylated and perfused with SAhIL2, 1 mouse was killed, and the tissue of the bladder mucosa was sampled for immunohistochemical assays to assess the persistence of the SAhIL2 immobilized on the biotinylated mucosal surface of the bladder wall.
A total of 125 female C57BL/6 mice was divided into five groups: the PBS control group, the soluble IL2 group, the SAGFP group, the SAhIL2 group, and the untreated group (blank control group); each with 25 mice. Treatment started on day 2 after the model had been established: SulfoNHSLCBiotin (1.25 mmol/L) was given in a 30min bladder perfusion. Then mice of each group received bladder perfusion with 0.1 mL of PBS, hIL2 (0.15 mg/mL), SAGFP (0.15 mg/mL), and SAhIL2 (0.15 mg/mL), respectively. A total of 6 continuous cycles of this treatment were conducted, 3 days per cycle. Survival states (mental state, diet, weight) and tumor growth (formation of tumor mass, tumor size, hematuria, distant metastasis) of the mice were observed every day. Survival time was recorded.
On day 60 after the establishment of the model, the SAhIL2 mice survived and the untreated mice were each challenged with 1 伊 10 6 MB49 cells. Tumor formation and survival time were recorded.
After the 6 cycles of treatment, mice in the SAhIL2 group were killed and their
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Splenocytes from the tumorfree or tumorbearing mice in the SAhIL2 group were harvested and stimulated by inactivated MB49 for 5 days. IL2 (20 U/mL) was added to maintain cell growth. These splenocytes served as effector cells and were adjusted to the density of 1 伊 10 6 /mL. MB49 cells served as target cells and were adjusted to the density of 1 伊 10 4 /mL. Both were added to a 96well plate at the effector to target ratios of 1:1, 25:1, and 50:1, 3 wells for each ratio. After 6 h of incubation, the supernatant fluids were collected (100 滋 L/well). The LDH method was used to assess the cytotoxicity of tumorspecific cytotoxic T lymphocytes (CTL) under the wavelength of 490 nm. CTL = (experimental value spontaneous release value of effector cells spontaneous release value of target cells)/ (maximum release value of target cells release value of target cells) 伊 100% . The PBS control group served as the negative control, and the untreated group as the blank control.
SPSS version 17.0 was used for statistical analysis. Survival was analyzed by the KaplanMeier method.
< 0.05 was considered as significantly different.
SAhIL2 fusion protein was found in the 12% SDSPAGE to have a polymeric structure in its nonreduced state (Figure 1 ). The result of Western blot analysis showed that both renatured monomeric forms and polymeric forms of SAhIL2 could bind to IL2 monoclonal antibodies and have a color reaction (Figure 1 ).
SAhIL2 on the biotinylated MB49 cell surface was detected by IL2 monoclonal antibody and a fluorochromeconjugated second antibody using flow cytometry. The results showed that biotinylated MB49 cells could be modified efficiently by SAhIL2 and the modification rate reached more than 90% (Figure 2 ). SAhIL2 could stimulate the proliferation of PHAactivated hPBL, which was concentrationdependent. The biologic activity of SAhIL2 was 1 伊 10 7 U/mL. Activity of immobilized SAhIL2 on the biotinylated MB49 cells was also assessed after the cells were broken apart by repeated freezing and thawing and the results showed that this immobilized protein retained the bioactivity of its hIL2 moiety that stimulates hPBL proliferation (Figure 3 ).
On days 1, 3, 5, and 7 after the bladder mucosa was biotinylated and perfused with SAhIL2, 1 mouse was killed, and the tissue of the bladder mucosa was sampled for immunohistochemical assay. The result showed that after SAhIL2 perfusion, SAhIL2 could be durably immobilized on the bladder mucosa as long as 7 days (Figure 4 ).
After the 6 cycles of treatment, mice in the SAhIL2 group were killed and their bladders were sampled for immunochemical In the PBS control and the SAGFP groups, palpable masses in the bladder region were found on days 79, and gross hematuria, a gradual decline in body weight, and gradually worsening mental states started on days 1720. Some of these mice died on day 19 and day 23. In the soluble IL2 and the SAhIL2 groups, some mice died or decreased in body weight on day 31 and day 35, respectively. These mice, compared with those in the PBS control group, had longer survival times and were more active. No significant change was observed in other mice.
On day 60 after MB49 implantation, all mice in the PBS control group died. Two of the 25 SAGFPtreated mice survived. Six of the 25 mice treated with soluble hIL2 survived. A total of 9 SAhIL2treated mice survived. Significant differences in survival time existed between the SAhIL2 group and the other 3 groups ( < 0.05) ( Figure 6A ). Furthermore, 5 out of 9 tumorfree mice in the SAhIL2 group still survived 60 days after a second intravesical wildtype MB49 tumor challenge, which was significantly different from the situation of the control group ( < 0.05 ) ( Figure 6B ). This indicates that the SAhIL 2treated mice established an immune memory mechanism. Inactivated MB49stimulated splenocytes from both the tumorfree or tumorbearing mice in the SAhIL2 group and the normal untreated mice were found to have a cytotoxic effect on MB49 cells. The result showed that cells from the tumorfree mice in the SAhIL2 group had a significantly stronger cytotoxic effect than the tumorbearing or the normal untreated mice ( < 0.01) (Figure 7) .
In recent years, there has been a rise in the incidence of bladder cancer. The most common type of bladder cancer is transitional cell carcinoma. Among patients with bladder cancer, about 75% have SBC, which is characterized by a high risk of relapse after surgery. Hence postoperative adjuvant therapy plays a key role and has become a hot research topic. Intravesical administration of Bacillus CalmetteGuè rin (BCG) after transurethral resection is by far the most effective local therapy for SBC [5] . However, BCG, as an attenuated vaccine, has high antigenicity, allergenicity, and residual toxicity. Intravesical administration of BCG may lead to various complications. Some patients also develop immunotolerance against BCG therapy [6] . Activation of the production of cytokines is believed to be responsible for the antitumor effects of BCG. Application of recombinant cytokines in the treatment patients with bladder cancer has shown some experimental effects. Sosnowski . [7] reported that significant reductions in tumor volume occurred when IL2 was intralesionally administered to subcutaneously transplanted tumors of mouse transitional cell carcinoma. Intravenous administration of IL2 in patients with advanced cancer has shown some clinical effects but also may lead to severe side effects due to its short halflife and thus the high dose required [9] . Moreover, the efficiency of gene transfection (or transduction) in situ in SBC is usually low, and the protein product of therapeutic genes has difficulty reaching an effective concentration and persisting for enough time at the local lesion. Potential safety concerns and immunogenicity of viral vectors are also problems yet to be solved in application [2] . In recent years, based on the ability of biotin to be incorporated easily onto the tumor cell surface and the strong interaction between biotin and streptavidin, we have developed a platform of cellsurface immobilization and modification that allows cytokines that serve as adjuvants to be immobilized on the tumor cell surface and thus enhance the effect of antitumor vaccines that induce active immunity. The SAGMCSFmodified mouse melanoma wholecell vaccine developed by us has shown promising effects in animal experiments [9] . In this study, the antitumor effect of the SAhIL2 bifunctional fusion protein, which may efficiently bind to biotinylated bladder mucosa via the extraordinarily strong affinity of SA for biotin, was studied in a mouse SBC model. The results showed that SAhIL2 could be immobilized efficiently and durably on the bladder mucosal surface for as long as 7 days. Immunochemistry suggested that SAhIL2 would significantly decrease 3 days after immobilization, which might be the result of the repair and renewal of the bladder mucosa and the degradation of SAhIL2 by urine protease. Thus the treatment cycles we adopted (3 days per cycle, totaling 6 continuous cycles) would enable us to keep the local concentrations of SAhIL2 at a high level for a relatively long time. Survival rates were significantly higher in the SAhIL2 group than in the other groups. Immunohistochemistry revealed a significant increase in IL2α receptorpositive lymphocytes at the tumor site in the SAhIL2 group compared with the PBS control group. Therefore we suppose that there are T cells and natural killer (NK) cells infiltrating in the tumor microenvironment, their proliferation and activation can be stimulated, and their cytotoxic effects can be enhanced by SAhIL2 perfusion and immobilization at the tumor focus.
The results also showed that SAGFP treatment could increase the survival rate of tumorbearing mice in comparison with the PBS control group ( < 0.05). This may be because streptavidin , as a bacterial protein , is highly immunogenic and able to stimulate the mice to mount a specific immune response [10] . On day 60 after MB49 implantation, 7 mice in the SAhIL2 group survived without tumor formation and receive a second intravesical MB49 tumor challenge. A total of 4 of them still survived without tumors 60 days after the challenge. Moreover, inactivated MB49 stimulated splenocytes from both the SAhIL2 group and the untreated group were found to have cytotoxic effects on MB49 cells. All these indicate that the SAhIL2treated mice established an antitumor immune memory mechanism and this novel treatment method may become a promising immunotherapy.
In summary, this study reported a novel immunotherapy for SBC. Immobilization of SAhIL2, a bifunctional fusion protein, on mouse bladder mucosa could inhibit tumor growth and increase the survival rate of tumorbearing mice. These findings may provide some experimental basis for the application of SAhIL2 in human bladder cancer treatment.
